

1 CLAIMS

2 What is claimed is:

3
4 Claim 1. A method of treating a human tumor in a mammal, wherein said tumor
5 expresses an antigen which specifically binds to a monoclonal antibody or antigen binding
6 fragment thereof which has the identifying characteristics of a monoclonal antibody
7 encoded by a clone deposited with the ATCC as accession number PTA-4621 comprising
8 administering to said mammal said monoclonal antibody in an amount effective to reduce
9 said mammal's tumor burden.

10
11 Claim 2. The method of claim 1 wherein said antibody is conjugated to a cytotoxic
12 moiety.

13
14 Claim 3. The method of claim 2 wherein said cytotoxic moiety is a radioactive
15 isotope.

16
17 Claim 4. The method of claim 1 wherein said antibody activates complement.

18
19 Claim 5. The method of claim 1 wherein said antibody mediates antibody
20 dependent cellular cytotoxicity.

21
22 Claim 6. The method of claim 1 wherein said antibody is a murine antibody.

1 Claim 7. The method of claim 1 wherein said antibody is a humanized antibody

2

3 Claim 8. The method of claim 1 wherein said antibody is a chimerized antibody.

4

5 Claim 9. An isolated monoclonal antibody or antigen binding fragments

6 thereof encoded by the clone deposited with the ATCC as PTA-4621.

7

8 Claim 10. The isolated antibody or antigen binding fragments of claim 9,

9 wherein said isolated antibody or antigen binding fragments thereof is humanized.

10

11 Claim 11. The isolated antibody or antigen binding fragments of claim 9

12 conjugated with a member selected from the group consisting of cytotoxic moieties,

13 enzymes, radioactive compounds, and hematogenous cells.

14

15 Claim 12. The isolated antibody or antigen binding fragments of claim 9,

16 wherein said isolated antibody or antigen binding fragments thereof is a chimerized

17 antibody.

18

19 Claim 13. The isolated antibody or antigen binding fragments of claim 9,

20 wherein said isolated antibody or antigen binding fragments thereof is a murine antibody.

21

22 Claim 14. The isolated clone deposited with the ATCC as PTA-4621.

1

2 Claim 15. A binding assay to determine presence of cancerous cells in a tissue

3 sample selected from a human tumor comprising:

4 providing a tissue sample from said human tumor ;

5 providing an isolated monoclonal antibody or antigen binding fragment thereof

6 encoded by the clone deposited with the ATCC as PTA-4621;

7 contacting said isolated monoclonal antibody or antigen binding fragment thereof

8 with said tissue sample; and

9 determining binding of said isolated monoclonal antibody or antigen binding

10 fragment thereof with said tissue sample;

11

12 whereby the presence of said cancerous cells in said tissue sample is indicated.

13

14 Claim 16. The binding assay of claim 15 wherein the human tumor tissue

15 sample is obtained from a tumor originating in a tissue selected from the group consisting

16 of colon, ovarian, lung, and breast tissue.

17

18 Claim 17. A process of isolating or screening for cancerous cells in a tissue

19 sample selected from a human tumor comprising:

20 providing a tissue sample from a said human tumor ;

1 providing an isolated monoclonal antibody or antigen binding fragment thereof
2 encoded by the clone deposited with the ATCC as PTA-4621;
3 contacting said isolated monoclonal antibody or antigen binding fragment thereof
4 with said tissue sample; and
5 determining binding of said isolated monoclonal antibody or antigen binding
6 fragment thereof with said tissue sample;
7 whereby said cancerous cells are isolated by said binding and their presence in said
8 tissue sample is confirmed.

9

10 Claim 18. The process of claim 17 wherein the human tumor tissue sample is
11 obtained from a tumor originating in a tissue selected from the group consisting of colon,
12 ovarian, lung, and breast tissue.

13

14

15

16

17

18

19

20